Internal Medicine, Medical Oncology · New York, NY
NPI
1275573644
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
380 Second Avenue, Suite 1003
New York, NY, 10010
Phone (212) 448-9555
Groups this clinician bills Medicare through
Medicare paid, 2024
$115K
1,613 services
Medicare patients, 2024
635
Average age 76
Drug cost, 2024
$3.7M
1,115 prescriptions
Company payments, 2025
$125
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maxim Kreditor was code 99214 (office e&m - established), 598 times for 262 patients. In total Maxim Kreditor billed 1,613 services in 18 codes, and Medicare paid $115K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 598 | 262 | $86.84 | $52K |
| 36415 Venipuncture Blood Collection | Office | 360 | 155 | $8.63 | $3,105 |
| 99213 Office E&M - Established | Office | 346 | 240 | $61.87 | $21K |
| 99204 Office E&M - New | Office | 147 | 147 | $116.55 | $17K |
| 99205 Office E&M - New | Office | 77 | 77 | $159.63 | $12K |
| 99223 Hospital E&M - Initial | Facility | 24 | 24 | $150.96 | $3,623 |
By year: 2022 $140K for 1,845 services; 2023 $149K for 1,986 services; 2024 $115K for 1,613 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 360 | 155 | $8.63 | $3,105 |
Medicare prescription drug claims, 2024
In 2024, the drug Maxim Kreditor prescribed most often to Medicare patients was Eliquis (Apixaban), with 159 prescriptions and refills. In total Maxim Kreditor wrote 1,115 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 159 | 229 | 36 | $136K |
| Letrozole Generic | 148 | 190 | 19 | $1,279 |
| Hydroxyurea Generic | 104 | 160 | 21 | $2,128 |
| Xarelto Rivaroxaban | 96 | 142 | 17 | $77K |
| Ondansetron Hcl Generic | 40 | 40 | 11 | $230 |
| Ibrance Palbociclib | 37 | 37 | Under 11 | $565K |
| Orgovyx Relugolix | 33 | 33 | Under 11 | $79K |
| Anastrozole Generic | 27 | 45 | Under 11 | $149 |
| Cyclosporine Generic | 26 | 26 | Under 11 | $12K |
| Anagrelide Hcl Generic | 24 | 24 | Under 11 | $1,913 |
| Jakafi Ruxolitinib Phosphate | 23 | 23 | Under 11 | $364K |
| Lynparza Olaparib | 23 | 23 | Under 11 | $370K |
| Calquence Acalabrutinib Maleate | 23 | 23 | Under 11 | $268K |
| Imbruvica Ibrutinib | 21 | 21 | Under 11 | $332K |
| Furosemide Generic | 19 | 28 | Under 11 | $40.03 |
Brand drugs: 503 claims; generic drugs: 612 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maxim Kreditor $125 ($125 in general payments such as food, travel and fees) from 3 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $49.37.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.